Table 1.
Primary and secondary outcomes of the EMPEROR-preserved trial (Anker et al. [134])
| Empagliflozin (n = 2997) | Placebo (n = 2991) | Hazard ratio or difference (95% confidence interval) | p value | |
|---|---|---|---|---|
| Overall primary composite endpoint—no. (%) | 415 (13.8) | 511 (17.1) | 0.79 (0.69–0.90) | < 0.001 |
| Hospitalisation for heart failure—no. (%) | 259 (8.6) | 352 (11.8) | 0.71 (0.60–0.83) | |
| Cardiovascular death—no. (%) | 219 (7.3) | 244 (8.2) | 0.91 (0.76–1.09) | |
| eGFR mean slope change per year (ml/min/1.73 m2) | − 1.25 ± 0.11 | − 2.62 ± 0.11 | 1.36 (1.06–1.66) | < 0.001 |
| Change in KCCQ score at 52 weeks | 4.51 ± 0.31 | 3.18 ± 0.31 | 1.32 (0.45–2.19) | |
| All-cause mortality—no. (%) | 422 (14.1) | 427 (14.3) | 1.00 (0.87–1.15) |